IRWD Sınıf A Ironwood Pharmaceuticals, Inc. - Class A Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026
$3,64
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,4152 haftanın en düşüğü
$5,7852 haftanın en yükseği
Piyasa Değeri (MRQ)
$601M
P/E (TTM)
4.7
Hisse Başına Kâr (TTM)
$0.77
Gelir (TTM)
$389M
rozetleriniz
52 Haftlık Aralık
$1–$6
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$6
P/E
4.7
ROE
-55.3%
Net Kâr Marjı
33.4%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
IRWD Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$3.64
Piyasa Değeri (MRQ)
$601M
P/E (TTM)
4.7
Hisse Başına Kâr (TTM)
$0.77
Gelir (TTM)
$389M
ROE (TTM)
-55.3%
52 Haftlık Aralık
$1–$6
IRWD Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 02 Nisan 2019 | 597-for-500 | İleri |
Ironwood Pharmaceuticals, Inc. - Class A Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea.
By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development. Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006. Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia.
By 2009, Ironwood had raised a total of $281M. In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14. Later that year it sold its interests in Microbia to DSM for an undisclosed sum.
Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere), a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012. Most of the marketing rights were licensed to Allergan and Astellas.
It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016.
Soclenicant (BNC-210; IW-2143) is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned.
In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board.
Despite having a billion dollar drug in Linzess, Ironwood - through a series of confounding decisions by management - has seen its stock price crater from a high of $21.16 on July 17, 2018, to its current price of 77 CENTS at the close of trading on August 1, 2025.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar100
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$296M2016-12-31 → 2025-12-31
Hisse Başına Kâr$0.152018-12-31 → 2025-12-31
Serbest Nakit Akışı$127M2016-12-31 → 2025-12-31
Net kar marjı33.4%2018-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | IRWD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 4.75Y ort. ≈96.0 | ≈96.0 | · | · | |
| F/S (TTM) | 1.55Y ort. ≈3.4 | ≈3.4 | 3.9 | Düşük değerli | |
| F/D (MRQ) | -3.75Y ort. ≈-0.7 | ≈-0.7 | · | · | |
| Price / FCF (Fiyat / Serbest Nakit Akışı) | 4.75Y ort. ≈7.0 | ≈7.0 | · | · | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | 4.75Y ort. ≈7.0 | ≈7.0 | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | -3.7 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | IRWD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 60.1%5Y ort. ≈-7.3% | ≈-7.3% | -81.6% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | 33.6%5Y ort. ≈-7.0% | ≈-7.0% | -81.6% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 53.3%5Y ort. ≈-12.4% | ≈-12.4% | -56.0% | En üst düzey | |
| Net Kâr Marjı (TTM) | 33.4%5Y ort. ≈-9.5% | ≈-9.5% | -86.5% | En üst düzey | |
| ROA (TTM) | 41.4%5Y ort. ≈-8.5% | ≈-8.5% | -53.6% | En üst düzey | |
| ROE (TTM) | -55.3%5Y ort. ≈-107.8% | ≈-107.8% | -68.2% | En üst düzey | |
| ROIC | -12.9%5Y ort. ≈82.3% | ≈82.3% | 2.1% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | IRWD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 6.15Y ort. ≈8.4 | ≈8.4 | 11.4 | Ortalamanın altında | |
| Quick Ratio (Cari Oran) | 1.15Y ort. ≈8.2 | ≈8.2 | 4.0 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | IRWD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -15.7%5Y ort. ≈-4.6% | ≈-4.6% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -10.3%5Y ort. ≈-3.8% | ≈-3.8% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | -5.3% | · | · | · | |
| EPS YoY (EPS YB) | 1400.0%5Y ort. ≈572.1% | ≈572.1% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 2629.2%5Y ort. ≈986.7% | ≈986.7% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -46.1% | · | · | · | |
| EPS CAGR 5Y (EPS Bileşik Yıllık Büyüme Oranı 5Y) | -25.7% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -48.4% | · | · | · | |
| Net Income CAGR 5Y (Net Gelir Bileşik Yıllık Büyüme Oranı 5Y) | -25.7% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | IRWD | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.85Y ort. ≈0.6 | ≈0.6 | 0.2 | En üst düzey | |
| Receivables Turnover (Alacak Devir Hızı) | 4.65Y ort. ≈3.7 | ≈3.7 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$3.0M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-5.1%
Sonraki Rapor
Kas 09, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 6, 2026 | $0.31 | $0.36 | -14.6% |
| 31 Mart 2026 | $0.24 | $0.24 | -2.0% | |
| 31 Aralık 2025 | $-0.01 | $0.01 | -198.0% | |
| 30 Eylül 2025 | $0.24 | $0.10 | 135.3% | |
| 30 Haziran 2025 | $0.14 | $0.04 | 243.1% | |
| 31 Mart 2025 | $-0.14 | $-0.05 | -194.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296M | $351M | $443M | $411M | $414M | $390M | $428M | $347M | $298M | $274M | $150M | $76M | |
| Cost of Revenue | · | · | · | · | · | $3M | $24M | $33M | $19M | $2M | $12.0K | $5M | |
| R&D Expense | $95M | $111M | $116M | $44M | $70M | $88M | $115M | $101M | $88M | $139M | $109M | $102M | |
| SG&A Expense | $82M | $144M | $158M | $116M | $111M | $140M | $172M | $220M | $231M | $173M | $125M | $118M | |
| Operating Expenses | $198M | $258M | $1.39B | $160M | $181M | $247M | $308M | $497M | $314M | $326M | $252M | $246M | |
| Operating Income | $99M | $93M | $-945M | $250M | $232M | $143M | $120M | $-151M | $-15M | $-52M | $-102M | $-169M | |
| Interest Expense | · | · | $22M | $8M | $31M | $29M | $37M | $38M | $36M | $39M | $31M | $21M | |
| Other Non-op | $193.0K | $640.0K | $-3M | $2M | $-32M | $-34M | $-61M | $-43M | $-40M | $-30M | $-41M | $-20M | |
| Pretax Income | $70M | $65M | $-948M | $252M | $201M | $109M | $59M | $-194M | · | · | · | · | |
| Income Tax | $46M | $64M | $83M | $77M | $-328M | $3M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $24M | $880.0K | $-1.00B | $175M | $528M | $106M | $22M | $-282M | $-117M | $-82M | $-143M | · | |
| EPS (Basic) | $0.15 | $0.01 | $-6.45 | $1.13 | $3.26 | $0.67 | $0.14 | $-1.85 | · | · | · | · | |
| EPS (Diluted) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | · | · | · | · | |
| Shares (Basic) | 161,842,000 | 159,083,000 | 155,435,000 | 154,366,000 | 162,245,000 | 159,427,000 | 156,023,000 | 152,634,000 | · | · | · | · | |
| Shares (Diluted) | 162,983,000 | 160,084,000 | 155,435,000 | 186,312,000 | 164,418,000 | 160,655,000 | 156,023,000 | 152,634,000 | · | · | · | · | |
| EBITDA | $100M | $94M | $-944M | $252M | $234M | $145M | $126M | $-233M | · | $-42M | $-90M | $-157M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $215M | $89M | $92M | $656M | $620M | $363M | $177M | $173M | $126M | $54M | $261M | $74M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $96M | $251M | $178M | $174M | |
| Receivables | $47M | $82M | $129M | $115M | $114M | $122M | $11M | $21M | $3M | $933.0K | $3M | $10.0K | |
| Inventory | · | · | · | · | · | · | $648.0K | · | $735.0K | $1M | · | $5M | |
| Prepaid Expense | $12M | $12M | $12M | $8M | $9M | $9M | $11M | $10M | $7M | $9M | $6M | $9M | |
| Current Assets | $274M | $182M | $233M | $781M | $745M | $496M | $307M | $266M | $312M | $380M | $500M | $288M | |
| PP&E (Net) | $3M | $4M | $6M | $6M | $8M | $9M | $12M | $8M | $17M | $21M | $21M | $30M | |
| PP&E (Gross) | $11M | $13M | $14M | $17M | $17M | $21M | $23M | $33M | $86M | $83M | $78M | $83M | |
| Accum. Depreciation | $8M | $8M | $9M | $11M | $10M | $12M | $10M | $26M | $69M | $62M | $57M | $53M | |
| Goodwill | · | · | · | · | · | · | $785.0K | $785.0K | $785.0K | $785.0K | · | · | |
| Intangibles | $2M | $3M | $4M | · | · | · | · | · | $160M | $166M | · | · | |
| Other Non-current Assets | $5M | $6M | $4M | $847.0K | $1M | $943.0K | $790.0K | $89.0K | $870.0K | $1M | $3M | $3M | |
| Total Assets | $397M | $351M | $471M | $1.10B | $1.13B | $559M | $403M | $332M | $606M | $710M | $619M | $329M | |
| Accounts Payable | $3M | $2M | $8M | $483.0K | $935.0K | $661.0K | $4M | $15M | $16M | $18M | $9M | $10M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $38M | $23M | $23M | |
| Short-term Debt | · | · | · | · | · | · | · | $48M | · | · | $25M | $11M | |
| Current Liabilities | $242M | $39M | $276M | $26M | $162M | $32M | $41M | $120M | $66M | $91M | $76M | $61M | |
| Capital Leases | $10M | $12M | $15M | $17M | $18M | $20M | $22M | $158.0K | · | $82.0K | $306.0K | $3M | |
| Other Non-current Liabilities | $22M | $17M | $28M | $10M | $4M | $2M | $734.0K | $3M | $5M | $8M | $10M | · | |
| Total Liabilities | $659M | · | · | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | $199M | $398M | $396M | $454M | $430M | · | · | · | · | $221M | · | |
| Total Debt | · | · | · | · | · | · | · | $48M | · | · | $25M | $11M | |
| Common Stock | $163.0K | $160.0K | $156.0K | $154.0K | $162.0K | $161.0K | $158.0K | $154.0K | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.70B | $-1.70B | $-696M | $-938M | $-1.47B | $-1.57B | $-1.59B | $-1.31B | $-1.19B | $-1.11B | $-967M | |
| AOCI | $-1M | $923.0K | $-3M | · | · | · | · | · | $-79.0K | $-7.0K | $-86.0K | $-19.0K | |
| Stockholders' Equity | $-262M | $-301M | $-346M | $652M | $606M | $63M | $-93M | $-196M | $10M | $67M | $95M | $89M | |
| Liabilities + Equity | $397M | $351M | $471M | $1.10B | $1.13B | $559M | $403M | $332M | $606M | $710M | $619M | $329M | |
| Shares Outstanding | 163,058,316 | 160,205,899 | 156,354,238 | 154,026,949 | 162,036,461 | 160,616,675 | 157,535,962 | 154,414,691 | · | · | · | · |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $6M | $4M | $6M | $10M | $12M | $12M | |
| Stock-based Comp | $17M | $30M | $32M | $27M | $22M | $31M | $31M | $41M | $31M | $29M | $25M | $26M | |
| Deferred Tax | $41M | $68M | $73M | $66M | $-333M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $8M | $6M | $981.0K | · | · | |
| Restructuring | $21M | $3M | $17M | · | $1M | $15M | $4M | $15M | · | · | · | $551.0K | |
| Other Non-cash | $44M | $4M | $1.08B | $5M | $43M | $29M | $-48M | $161M | · | · | · | · | |
| Operating Cash Flow | $127M | $104M | $183M | $274M | $262M | $169M | $11M | $-71M | $-101M | $-26M | $-107M | $-156M | |
| CapEx | $34.0K | $142.0K | $273.0K | $136.0K | $265.0K | $2M | $7M | $351.0K | $3M | $4M | $4M | $4M | |
| Investing Cash Flow | $-34.0K | $-142.0K | $-1.03B | $-136.0K | $-265.0K | $-2M | $-11M | $89M | $151M | $-178M | $-9M | $-57M | |
| Debt Issued | · | · | · | · | · | · | · | · | $146M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | $190M | |
| Stock Repurchased | · | · | · | $126M | $24M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | $-126M | $-24M | · | · | · | · | · | · | $190M | |
| Financing Cash Flow | $216.0K | $-107M | $277M | $-238M | $-5M | $19M | $-1M | $30M | $20M | $-4M | $303M | $211M | |
| Net Change in Cash | $127M | $-4M | $-566M | $36M | $257M | $186M | $-2M | $48M | $71M | $-208M | $187M | · | |
| Taxes Paid | $4M | $8M | $10M | $5M | $3M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | $127M | $103M | $183M | $274M | $262M | $167M | $4M | $-80M | · | $-30M | $-111M | $-159M | |
| Levered FCF | · | · | $160M | $268M | $180M | $138M | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% | 36.7% | 28.0% | -68.9% | · | -18.9% | -68.3% | -221.6% | |
| Net Margin | 8.1% | 0.25% | -226.4% | 42.6% | 127.7% | 27.3% | 5.0% | -81.5% | · | · | · | · | |
| Pretax Margin | 23.6% | 18.6% | -214.1% | 61.5% | 48.5% | 28.0% | · | · | · | · | · | · | |
| EBITDA Margin | 33.6% | 26.8% | -213.3% | 61.3% | 56.5% | 37.3% | 29.3% | -67.2% | · | -15.2% | -60.5% | -205.4% | |
| ROA | 6.4% | 0.21% | -127.5% | 15.7% | 62.7% | 22.1% | 5.9% | -60.2% | · | · | · | · | |
| ROE | -8.5% | -0.27% | -654.9% | 29.9% | 94.6% | 309.8% | -17.5% | 143.5% | · | · | · | · | |
| ROIC | -12.9% | -0.42% | 297.1% | 26.6% | 101.0% | 222.6% | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 4.7 | 0.8 | 30.6 | 4.6 | 15.4 | 7.5 | 2.2 | · | 4.2 | 6.5 | 4.8 | |
| Quick Ratio | 1.1 | 4.4 | 0.8 | 30.2 | 4.5 | 15.1 | 4.6 | 1.6 | · | 3.4 | 5.8 | 4.1 | |
| Debt / Equity | · | · | · | · | · | · | · | -0.2 | · | · | 0.3 | 0.1 | |
| Interest Coverage | · | · | -43.7 | 32.9 | 7.5 | 4.8 | 3.3 | -6.3 | · | -1.3 | -3.3 | -8.0 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.9 | 0.6 | 0.4 | 0.5 | 0.8 | 1.2 | 0.7 | · | 0.4 | 0.3 | 0.2 | |
| Inventory Turnover | · | · | · | · | · | · | 34.5 | · | · | 3.5 | · | 1.9 | |
| Receivables Turnover | 4.6 | 3.3 | 3.6 | 3.6 | 3.5 | 5.8 | 26.6 | 28.7 | · | 143.5 | 103.4 | 292.3 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.61 | $-1.88 | $-2.21 | $4.24 | $3.74 | $0.39 | $-0.59 | · | · | · | · | · | |
| Revenue / Share | $1.82 | $2.20 | $2.85 | $2.20 | $2.52 | $2.42 | · | · | · | · | · | · | |
| Cash Flow / Share | $0.78 | $0.65 | $1.18 | $1.47 | $1.59 | $1.05 | · | · | · | · | · | · | |
| Cash / Share | $1.32 | $0.55 | $0.59 | $4.26 | $3.83 | $2.26 | $1.12 | · | · | · | · | · | |
| EPS (TTM) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | $-2.38 | $-2.38 | $-2.38 | $-2.38 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -15.7% | -20.6% | 7.8% | -0.76% | 6.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -10.3% | -5.3% | 4.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -5.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 1400.0% | · | · | -70.1% | 386.4% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -46.1% | -85.4% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -25.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2629.2% | · | · | -66.9% | 397.7% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -48.4% | -88.1% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -25.7% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $296M | $351M | $443M | $411M | $414M | $390M | $428M | $347M | $298M | $274M | $150M | $76M | |
| Net Income TTM | $24M | $880.0K | $-1.00B | $175M | $528M | $106M | $22M | $-282M | $-117M | $-82M | $-143M | · | |
| Market Cap | $550M | $710M | $1.79B | $1.91B | $1.89B | $1.83B | $2.10B | · | · | · | · | · | |
| P/E | 22.5 | 443.0 | -1.8 | 12.9 | 3.6 | 17.3 | 95.1 | -4.7 | -5.3 | -5.4 | -4.1 | -5.4 | |
| P/S | 1.9 | 2.0 | 4.0 | 4.6 | 4.6 | 4.7 | 4.9 | · | · | · | · | · | |
| P/B | -2.1 | -2.4 | -5.2 | 2.9 | 3.1 | 29.2 | -22.5 | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 2.9 | 3.1 | 29.2 | · | · | · | · | · | · | |
| P / Cash Flow | 4.3 | 6.9 | 9.8 | 7.0 | 7.2 | 10.8 | 195.5 | · | · | · | · | · | |
| P / FCF | 4.3 | 6.9 | 9.8 | 7.0 | 7.2 | 11.0 | 593.0 | · | · | · | · | · | |
| Earnings Yield | 4.5% | 0.23% | -56.4% | 7.8% | 27.5% | 5.8% | 1.1% | -21.3% | -19.0% | -18.6% | -24.5% | -18.6% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113M | $107M | $48M | $122M | $85M | $41M | $91M | $92M | $94M | $75M | $118M | $114M | $107M | $104M | $107M | $109M | |
| R&D Expense | $22M | $22M | $22M | $22M | $23M | $27M | $25M | $30M | $30M | $26M | $36M | $33M | $35M | $13M | $10M | $12M | |
| SG&A Expense | $11M | $12M | $19M | $22M | $17M | $24M | $34M | $36M | $37M | $38M | $39M | $36M | $52M | $31M | $28M | $29M | |
| Operating Expenses | $34M | $34M | $41M | $47M | $40M | $70M | $59M | $66M | $69M | $64M | $80M | $74M | $1.19B | $44M | $39M | $40M | |
| Operating Income | $79M | $73M | $7M | $75M | $45M | $-29M | $31M | $26M | $25M | $11M | $38M | $40M | $-1.08B | $60M | $68M | $68M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $7M | · | $10M | $2M | $2M | · | $2M | |
| Other Non-op | $42.0K | $42.0K | $77.0K | $40.0K | $39.0K | $37.0K | $21M | $-8M | $-6M | $-6M | $-7M | $-8M | $7M | $6M | $4M | $1M | |
| Pretax Income | $74M | $65M | $455.0K | $68M | $38M | $-36M | $24M | $17M | $19M | $5M | $30M | $32M | $-1.08B | $66M | $72M | $70M | |
| Income Tax | $22M | $24M | $3M | $28M | $14M | $1M | $22M | $14M | $20M | $9M | $32M | $18M | $13M | $20M | $23M | $20M | |
| Net Income | $51M | $41M | $-2M | $40M | $24M | $-37M | $2M | $4M | $-860.0K | $-4M | $-1M | $15M | $-1.06B | $46M | $49M | $50M | |
| EPS (Basic) | $0.31 | $0.25 | $-0.01 | $0.25 | $0.15 | $-0.23 | $0.01 | $0.02 | $-0.01 | $-0.03 | $-0.01 | $0.10 | $-6.84 | $0.30 | $0.31 | $0.33 | |
| EPS (Diluted) | $0.31 | $0.24 | $-0.01 | $0.23 | $0.14 | $-0.23 | $0.01 | $0.02 | $-0.01 | $-0.03 | $-0.01 | $0.09 | $-6.84 | $0.25 | $0.26 | $0.28 | |
| Shares (Basic) | 164,405,000 | 163,451,000 | · | 162,215,000 | 161,723,000 | 160,974,000 | · | 159,706,000 | 159,014,000 | 157,700,000 | · | 155,886,000 | 155,367,000 | 154,452,000 | · | 153,066,000 | |
| Shares (Diluted) | 167,179,000 | 166,690,000 | · | 177,764,000 | 176,837,000 | 160,974,000 | · | 160,232,000 | 159,014,000 | 157,700,000 | · | 186,891,000 | 155,367,000 | 186,680,000 | · | 184,465,000 | |
| EBITDA | $79M | $73M | · | $75M | $45M | $-29M | · | $26M | $25M | $11M | · | $40M | $-1.08B | $60M | · | $68M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $220M | $215M | $140M | $93M | $108M | $89M | $88M | $106M | $122M | $92M | $110M | $175M | $740M | $656M | $574M | |
| Receivables | $113M | $106M | $47M | $120M | $86M | $40M | $82M | $76M | $58M | $72M | $129M | $125M | $119M | $116M | · | $117M | |
| Prepaid Expense | $7M | $6M | $12M | $13M | $13M | $12M | $12M | $14M | $15M | $15M | $12M | $18M | $22M | $9M | · | $7M | |
| Current Assets | $199M | $332M | $274M | $274M | $192M | $161M | $182M | $179M | $178M | $208M | $233M | $254M | $318M | $866M | · | $699M | |
| PP&E (Net) | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $11M | · | · | · | $13M | · | · | · | $14M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $8M | · | · | · | $8M | · | · | · | $9M | · | · | · | · | · | |
| Intangibles | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | · | · | |
| Other Non-current Assets | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | $4M | $4M | $4M | $820.0K | · | $863.0K | |
| Total Assets | $285M | $435M | $397M | $396M | $343M | $327M | $351M | $390M | $396M | $439M | $471M | $524M | $603M | $1.16B | · | $1.04B | |
| Accounts Payable | $911.0K | $3M | $3M | $2M | $1M | $6M | $2M | $3M | $3M | $6M | $8M | $5M | $4M | $118.0K | · | $795.0K | |
| Current Liabilities | $33M | $236M | $242M | $243M | $233M | $48M | $39M | $49M | $46M | $252M | $276M | $281M | $305M | $24M | · | $27M | |
| Capital Leases | $9M | $9M | $10M | $10M | $11M | $12M | $12M | $13M | $13M | $14M | $15M | $15M | $16M | $16M | · | $17M | |
| Other Non-current Liabilities | $21M | $21M | $22M | $22M | $22M | $17M | $17M | $40M | $35M | $29M | $28M | $31M | $31M | $12M | · | $9M | |
| Total Liabilities | $447M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | $200M | $199M | $199M | · | $199M | $199M | $398M | · | $397M | $397M | $397M | · | $396M | |
| Common Stock | $165.0K | $165.0K | $163.0K | $163.0K | $162.0K | $162.0K | $160.0K | $160.0K | $160.0K | $159.0K | $156.0K | $156.0K | $156.0K | $155.0K | · | $153.0K | |
| Retained Earnings | $-1.58B | $-1.63B | $-1.67B | $-1.67B | $-1.71B | $-1.74B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.71B | $-651M | · | $-745M | |
| AOCI | $-324.0K | $-795.0K | $-1M | $-2M | $-2M | $294.0K | $923.0K | $-2M | $-470.0K | $-922.0K | $-3M | $-752.0K | · | · | · | · | |
| Stockholders' Equity | $-162M | $-217M | $-262M | $-264M | $-308M | $-334M | $-301M | $-311M | $-322M | $-331M | $-346M | $-323M | $-346M | $707M | · | $591M | |
| Liabilities + Equity | $285M | $435M | $397M | $396M | $343M | $327M | $351M | $390M | $396M | $439M | $471M | $524M | $603M | $1.16B | · | $1.04B | |
| Shares Outstanding | 165,239,947 | 164,613,406 | 163,058,316 | 162,678,647 | 162,434,130 | 161,809,432 | 160,205,899 | 160,015,888 | 159,739,001 | 158,957,123 | 156,354,238 | 156,125,676 | 156,027,648 | 155,346,103 | · | 153,319,417 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $8M | $9M | $8M | $9M | $8M | $8M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $20M | $16M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $639.0K | $5M | · | · | · | · | |
| Operating Cash Flow | $58M | $5M | $75M | $48M | $-15M | $20M | $15M | $10M | $33M | $45M | $36M | $32M | $35M | $80M | $79M | $69M | |
| CapEx | · | · | $-1.0K | $2.0K | $2.0K | $31.0K | $0 | $16.0K | $58.0K | $68.0K | $211.0K | $49.0K | $0 | $13.0K | $-27.0K | $66.0K | |
| Investing Cash Flow | · | · | $1.0K | $-2.0K | $-2.0K | $-31.0K | $0 | $-16.0K | $-58.0K | $-68.0K | $-4M | $-23M | $-999M | $-13.0K | $27.0K | $-66.0K | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | · | · | $122.0K | $0 | $88.0K | $6.0K | $-15M | $-27M | $-49M | $-16M | $-51M | $-75M | $399M | $4M | $3M | $797.0K | |
| Net Change in Cash | $-141M | $5M | $75M | $48M | $-16M | $20M | $348.0K | $-17M | $-16M | $29M | $-19M | $-65M | $-565M | $84M | $82M | $70M | |
| Free Cash Flow | · | · | · | · | · | $20M | · | · | · | $45M | · | · | · | $80M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $51M | · | · | · | $79M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 70.2% | 68.1% | · | 61.8% | 53.2% | -70.8% | · | 28.0% | 26.5% | 14.7% | · | 35.2% | -1008.7% | 57.8% | · | 63.0% | |
| Net Margin | 45.4% | 38.3% | · | 32.8% | 27.7% | -90.9% | · | 4.0% | -0.91% | -5.6% | · | 13.5% | -989.2% | 43.9% | · | 46.3% | |
| Pretax Margin | 65.2% | 61.2% | · | 55.7% | 44.4% | -88.2% | · | 19.0% | 20.0% | 6.6% | · | 28.1% | -1002.2% | 63.3% | · | 64.3% | |
| EBITDA Margin | 70.2% | 68.1% | · | 61.8% | 53.2% | -70.8% | · | 28.0% | 26.5% | 14.7% | · | 35.2% | -1008.7% | 57.8% | · | 63.0% | |
| ROA | 16.3% | 10.7% | · | 10.2% | 6.4% | -9.8% | · | 0.80% | -0.17% | -0.52% | · | 2.0% | -131.9% | 4.3% | · | 4.8% | |
| ROE | -21.8% | -14.8% | · | -13.9% | -7.5% | 11.2% | · | -1.1% | 0.26% | -2.2% | · | 11.4% | -1279.3% | 7.4% | · | 8.6% | |
| ROIC | -34.1% | -20.9% | · | -16.8% | -9.2% | 9.0% | · | -1.7% | 0.35% | 2.8% | · | -5.4% | 317.2% | 5.9% | · | 8.3% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.1 | 1.4 | · | 1.1 | 0.8 | 3.3 | · | 3.6 | 3.9 | 0.8 | · | 0.9 | 1.0 | 36.3 | · | 25.8 | |
| Quick Ratio | 5.8 | 1.4 | · | 1.1 | 0.8 | 3.1 | · | 3.3 | 3.6 | 0.8 | · | 0.8 | 1.0 | 35.9 | · | 25.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 1.5 | · | 4.1 | -588.7 | 39.4 | · | 44.9 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.1 | 1.5 | · | 1.2 | 1.2 | 0.7 | · | 0.9 | 1.1 | 0.8 | · | 0.9 | 1.0 | 1.0 | · | 1.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.98 | $-1.32 | · | $-1.62 | $-1.90 | $-2.06 | · | $-1.95 | $-2.01 | $-2.08 | · | $-2.07 | $-2.22 | $4.55 | · | $3.86 | |
| Revenue / Share | $0.68 | $0.64 | · | $0.69 | $0.48 | $0.26 | · | $0.57 | $0.59 | $0.47 | · | $0.61 | $0.69 | $0.56 | · | $0.59 | |
| Cash Flow / Share | · | $0.03 | · | · | · | $0.12 | · | · | · | $0.29 | · | · | · | $0.43 | · | · | |
| Cash / Share | $0.48 | $1.34 | · | $0.86 | $0.57 | $0.67 | · | $0.55 | $0.66 | $0.76 | · | $0.71 | $1.12 | $4.77 | · | $3.75 | |
| EPS (TTM) | $0.77 | $0.60 | · | $0.15 | $-0.06 | $-0.21 | · | $-0.03 | $0.04 | $-6.79 | · | $-6.24 | $-6.05 | $1.00 | · | $0.93 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $389M | $362M | · | $339M | $309M | $318M | · | $378M | $401M | $414M | · | $432M | $427M | $417M | · | $421M | |
| Net Income TTM | $130M | $102M | · | $29M | $-8M | $-32M | · | $-2M | $9M | $-1.05B | · | $-952M | $-917M | $182M | · | $168M | |
| Market Cap | $696M | $578M | · | $213M | $117M | $238M | · | $659M | $1.04B | $1.38B | · | $1.50B | $1.66B | $1.63B | · | $1.59B | |
| P/E | 5.5 | 5.8 | · | 8.7 | -12.0 | -7.0 | · | -137.3 | 163.0 | -1.3 | · | -1.5 | -1.8 | 10.5 | · | 11.1 | |
| P/S | 1.8 | 1.6 | · | 0.6 | 0.4 | 0.7 | · | 1.7 | 2.6 | 3.3 | · | 3.5 | 3.9 | 3.9 | · | 3.8 | |
| P/B | -4.3 | -2.7 | · | -0.8 | -0.4 | -0.7 | · | -2.1 | -3.2 | -4.2 | · | -4.7 | -4.8 | 2.3 | · | 2.7 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | · | 2.3 | · | 2.7 | |
| P / Cash Flow | · | 112.8 | · | · | · | 11.9 | · | · | · | 30.8 | · | · | · | 20.4 | · | · | |
| Earnings Yield | 18.3% | 17.1% | · | 11.5% | -8.3% | -14.3% | · | -0.73% | 0.61% | -78.0% | · | -64.8% | -56.9% | 9.5% | · | 9.0% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $296M | $351M | $443M | $411M | $414M |
| Faaliyet Kâr Marjı % | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% |
| Net Gelir | $24M | $880.0K | $-1.00B | $175M | $528M |
| Seyreltilmiş Hisse Başı Kâr | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 1.1 | 4.7 | 0.8 | 30.6 | 4.6 |
| Cari Oran | 1.1 | 4.4 | 0.8 | 30.2 | 4.5 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $127M | $103M | $183M | $274M | $262M |
Kurumsal Sahipler (13F) 229 dosya · $708.7M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
229
Tutulan Değer
$708.7M
Yeni pozisyonlar
25
Çıkan pozisyonlar
32
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 25 (-35 önceki Ç'ye göre) | 32 (+7 önceki Ç'ye göre) | 75 (-11 önceki Ç'ye göre) | 85 (+30 önceki Ç'ye göre) | -11.8M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $74.889.826 | 17.788.557 | 10,57% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $58.653.720 | 13.932.000 | 8,28% | Hisse senetleri |
| VANGUARD GROUP INC | $53.779.120 | 15.958.196 | 7,59% | Hisse senetleri |
| Sarissa Capital Management LP | $38.684.153 | 9.188.635 | 5,46% | Hisse senetleri |
| STATE STREET CORP | $37.088.420 | 8.809.601 | 5,23% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $36.558.810 | 8.683.803 | 5,16% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $33.651.481 | 7.993.226 | 4,75% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.821.819 | 6.608.508 | 3,93% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $27.221.528 | 6.465.921 | 3,84% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $23.211.225 | 5.513.355 | 3,28% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $20.345.036 | 4.831.657 | 2,87% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $19.181.135 | 4.556.089 | 2,71% | Hisse senetleri |
| MARSHALL WACE, LLP | $18.061.293 | 4.290.093 | 2,55% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $17.117.708 | 4.065.964 | 2,42% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $13.951.132 | 3.313.808 | 1,97% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $13.902.439 | 3.302.242 | 1,96% | Hisse senetleri |
| FEDERATED HERMES, INC. | $13.603.512 | 3.231.238 | 1,92% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $12.701.945 | 3.017.089 | 1,79% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $10.622.431 | 2.522.891 | 1,50% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $10.582.137 | 3.140.100 | 1,49% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $9.967.146 | 2.367.493 | 1,41% | Hisse senetleri |
| MORGAN STANLEY | $7.830.240 | 1.859.914 | 1,10% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $7.627.316 | 1.811.714 | 1,08% | Hisse senetleri |
| NORTHERN TRUST CORP | $5.784.430 | 1.373.974 | 0,82% | Hisse senetleri |
| Hillsdale Investment Management Inc. | $5.264.302 | 1.250.428 | 0,74% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $5.078.094 | 1.206.198 | 0,72% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $4.875.761 | 1.158.138 | 0,69% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $4.379.810 | 1.040.335 | 0,62% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $4.239.382 | 1.006.979 | 0,60% | Hisse senetleri |
| FMR LLC | $3.828.942 | 909.488 | 0,54% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $3.277.548 | 778.515 | 0,46% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $3.052.608 | 725.085 | 0,43% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $2.772.104 | 658.457 | 0,39% | Hisse senetleri |
| IEQ CAPITAL, LLC | $2.364.286 | 561.588 | 0,33% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $2.361.970 | 561.038 | 0,33% | Hisse senetleri |
| PRUDENTIAL FINANCIAL INC | $2.261.608 | 537.199 | 0,32% | Hisse senetleri |
| Bank of New York Mellon Corp | $2.142.384 | 508.880 | 0,30% | Hisse senetleri |
| CITADEL ADVISORS LLC | $2.115.117 | 502.403 | 0,30% | Hisse senetleri |
| VOYA INVESTMENT MANAGEMENT LLC | $2.039.535 | 484.450 | 0,29% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $1.973.737 | 468.821 | 0,28% | Hisse senetleri |
| SEI INVESTMENTS CO | $1.934.150 | 459.417 | 0,27% | Hisse senetleri |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $1.897.127 | 540.492 | 0,27% | Hisse senetleri |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $1.847.815 | 438.911 | 0,26% | Hisse senetleri |
| Inspire Investing, LLC | $1.789.893 | 509.941 | 0,25% | Hisse senetleri |
| SEGALL BRYANT & HAMILL, LLC | $1.717.949 | 408.064 | 0,24% | Hisse senetleri |
| Invesco Ltd. | $1.697.510 | 403.209 | 0,24% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.670.528 | 396.800 | 0,24% | Satım opsiyonu |
| Man Group plc | $1.650.813 | 392.117 | 0,23% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $1.641.029 | 389.793 | 0,23% | Hisse senetleri |
| UBS Group AG | $1.639.917 | 389.529 | 0,23% | Hisse senetleri |
Aktivistler ve %5+ sahipler 4 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J. Denner | 19 Mart 2026 | 5,80% | Değişiklik | · | SEC |
| Ironwood Pharmaceuticals, Inc. | 07 Temmuz 2023 | · | İlk başvuru | M&A / satış | SEC |
| OR ×3 başvurular | 01 Mart 2021 | · | İlk başvuru | · | SEC |
| 09 Kasım 2020 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 41 içeriden öğrenenler · 18 yöneticiler · 22 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Thomas A Mccourt | Chief Executive Officer | 10 Mart 2026 A | 1.898.838 | 0 | 2 | $-739.929 |
| Mark Mallon | Chief Executive Officer | 26 Şubat 2021 S | 470.605 | 0 | 0 | $0 |
| Peter M. Hecht | Chief Executive Officer | 01 Nisan 2019 D | 2.217.366 | 0 | 0 | $0 |
| Gregory S. Martini | Chief Financial Officer | 10 Mart 2026 A | 297.213 | 0 | 2 | $-81.888 |
| Sravan Kumar Emany | SVP, COO and CFO | 18 Kasım 2024 S | 309.572 | 0 | 0 | $0 |
| Gina Consylman | SVP, CFO & Treasurer | 26 Mart 2021 A | 392.616 | 0 | 0 | $0 |
| Jason Rickard | SVP, Chief Operating Officer | 08 Mart 2023 A | 376.316 | 0 | 0 | $0 |
| William Huyett | Chief Operating Officer | 01 Nisan 2019 D | 27.546 | 0 | 0 | $0 |
| Michael J Higgins | Chief Operating Officer | 23 Aralık 2014 M | 329.102 | 0 | 0 | $0 |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 20 Temmuz 2026 A | 137.036 | 0 | 0 | $0 |
| Ronald Silver | PFO & PAO | 07 Temmuz 2026 S | 313.680 | 0 | 4 | $-831.183 |
| Tammi L Gaskins | Chief Commercial Officer | 10 Mart 2026 A | 350.350 | 0 | 3 | $-100.301 |
| Minardo John | Chief Legal Officer | 10 Mart 2026 A | 500.498 | 0 | 2 | $-136.177 |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 10 Mart 2026 A | 658.037 | 0 | 2 | $-121.586 |
| Andrew Davis | SVP, Chief Business Officer | 18 Kasım 2024 S | 284.685 | 0 | 0 | $0 |
| Conor Kilroy | SVP, GC & Secretary | 26 Şubat 2021 S | 122.336 | 0 | 0 | $0 |
| Kelly Macdonald | Chief Accounting Officer | 04 Aralık 2020 M | 93.041 | 0 | 0 | $0 |
| Halley E Gilbert | Chief Admin Officer & SVP | 21 Şubat 2020 S | 265.991 | 0 | 0 | $0 |
| DENNER ALEXANDER J | Yönetim kurulu üyesi | 15 Eylül 2026 A | 327.549 | 0 | 2 | $-20.530.448 |
| Catherine Moukheibir | Yönetim kurulu üyesi | 16 Haziran 2026 A | 181.425 | 0 | 0 | $0 |
| Jon R Duane | Yönetim kurulu üyesi | 16 Haziran 2026 A | 253.820 | 0 | 0 | $0 |
| Marla L Kessler | Yönetim kurulu üyesi | 16 Haziran 2026 A | 229.364 | 0 | 0 | $0 |
| Jay Shepard | Yönetim kurulu üyesi | 16 Haziran 2026 A | 235.036 | 0 | 0 | $0 |
| Julie Mchugh | Yönetim kurulu üyesi | 16 Haziran 2026 S | 250.749 | 0 | 1 | $-80.460 |
| Mark G Currie | Yönetim kurulu üyesi | 16 Haziran 2026 A | 676.900 | 0 | 0 | $0 |
| Andrew Dreyfus | Yönetim kurulu üyesi | 10 Haziran 2025 A | 228.313 | 0 | 0 | $0 |
| Edward P Owens | Yönetim kurulu üyesi | 02 Haziran 2021 A | 241.720 | 0 | 0 | $0 |
| Lawrence S Olanoff | Yönetim kurulu üyesi | 02 Haziran 2021 A | 91.395 | 0 | 0 | $0 |
| Amy Schulman | Yönetim kurulu üyesi | 01 Nisan 2019 D | 38.242 | 0 | 0 | $0 |
| Marsha Fanucci | Yönetim kurulu üyesi | 01 Nisan 2019 D | 132.663 | 0 | 0 | $0 |
| Douglas E Williams | Yönetim kurulu üyesi | 01 Nisan 2019 D | 87.800 | 0 | 0 | $0 |
| Terrance McGuire | Yönetim kurulu üyesi | 01 Nisan 2019 D | 73.630 | 0 | 0 | $0 |
| WALSH CHRISTOPHER T PHD | Yönetim kurulu üyesi | 15 Mart 2017 A | 71.499 | 0 | 0 | $0 |
| George N Conrades | Yönetim kurulu üyesi | 03 Haziran 2015 A | 62.221 | 0 | 0 | $0 |
| David A Ebersman | Yönetim kurulu üyesi | 13 Mart 2015 A | 29.714 | 0 | 0 | $0 |
| COOK JOSEPH C JR | Yönetim kurulu üyesi | 12 Mart 2015 S | 304.080 | 0 | 0 | $0 |
| David Evans Shaw | Yönetim kurulu üyesi | 14 Mart 2014 A | 64.306 | 0 | 0 | $0 |
| VR Management LLC | 10% sahip | 15 Ocak 2013 J | 2.442 | 0 | 0 | $0 |
| FMR LLC | 10% sahip | 10 Temmuz 2012 S | 2.340.891 | 0 | 0 | $0 |
| Thomas Graney | · | 27 Şubat 2017 A | 42.013 | 0 | 0 | $0 |
| Bryan E Roberts | · | 15 Haziran 2015 A | 31.951 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 33 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,60% | 371.823 NS | 31 Temmuz 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,48% | 28.214 SH | 01 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,16% | 186.886 NS | 31 Temmuz 2026 | N-PORT |
| IWC · iShares Trust | 0,15% | 554.146 SH | 11 Eylül 2026 | Günlük |
| VFVA · VANGUARD WELLINGTON FUND | 0,13% | 267.285 SH | 19 Ağustos 2026 | Günlük |
| CALF · Pacer Funds Trust | 0,12% | 1.079.411 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,11% | 521.040 SH | 19 Ağustos 2026 | Günlük |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 135.991 NS | 31 Temmuz 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 466.785 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 0,05% | 1.214.535 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,04% | 2.553 NS | 31 Temmuz 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 11.684 SH | 01 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 287.297 SH | 01 Ekim 2026 | Günlük |
| IWO · iShares Trust | 0,04% | 1.446.914 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 165.563 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,02% | 78.252 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4.241.422 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 943.404 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,01% | 534.999 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.677.357 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 437.643 SH | 19 Ağustos 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 272.518 NS | 31 Temmuz 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,00% | 8.700 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 11.833 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 197.587 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 41.467 SH | 09 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 32.200 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 11.941 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.781.484 SH | 19 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.494 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.354 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 92.403 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 383.496 SH | 11 Eylül 2026 | Günlük |
IRWD Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 10 analist
AL
Medyan hedef
$5.35
+47,0%
2 20,0%
Güçlü Al
5 50,0%
Al
3 30,0%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
4 analist · 2026-09-30Ortalama hedef $6.10 +67,6%
← Tüm hedeflerin altında
Mevcut fiyat $3.64
Düşük$3.70
Ortalama$6.10
Yüksek$10.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | · |
| STTK | $231M | -5.2 | -82.5% | -4880.9% | -70.0% | · |
| MDXG | $1.00B | 21.2 | 20.0% | 11.6% | 20.5% | 82.6% |
| AURA | $347M | -3.1 | -29.7% | -1601.4% | -68.2% | · |
| CLYM | $191M | -4.5 | · | · | -34.6% | · |
| CTMX | $725M | · | -44.8% | -22.8% | -15.9% | · |
| SGMT | · | -3.7 | · | · | -42.3% | · |
| MPLT | $773M | -0.9 | · | · | -151.1% | · |
| PRME | $626M | -2.6 | 55.3% | -4342.4% | -221.4% | · |
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 6, 2026